Pharmaceutical Executive-08-01-2003

Pharmaceutical Executive

The $46 Million Man

August 01, 2003

From the Editor

When I was a kid, I remember reading magazine articles that set out to determine the worth of the human body-not its personal value, or its ability to produce valuable labor, but just the market value of the chemicals that composed it. The figure I remember hearing was $1.98. Pocket change for the crown of creation.

Table of Contents

August 01, 2003

Table of Contents

More Than Just a Pretty Face

August 01, 2003

Features

Before Botox became a popular beauty treatment, Allergan was just a small ophthalmic business that made prescription eye therapies and contact lens care products.

10 Classic Mistakes and how to avoid them

August 01, 2003

Features

Since the pharma industry uploaded its very first websites in 1994, marketers' perception of the web has moved from intriguing novelty, to must-have status symbol, to vital communications channel for both patients and physicians. Yet even as product managers devote more resources to their brand-name product websites, many still commit fundamental errors with alarming frequency.

Managing the Innovator

August 01, 2003

Features

Innovative products, and the research and development teams that produce them, are pharma's life blood. So it's no surprise that, according to PE's 2003 Top 50 Pharma, the largest 20 pharma companies alone spent $45.5 billion on R&D.

Detailing Gets Personal

August 01, 2003

Features

As pharma sales forces grow and their productivity declines, the question on everyone's mind is, "Has the traditional detail lost its punch?" The answer is unequivocally no. The sales force is still the best medium for forging valued and trusted relationships with targeted physicians.

Protecting IP Throughout the Product Lifecycle

August 01, 2003

Features

Now that patents on several blockbuster drugs have expired, the industry-feeling the pinch-has focused its attention on intellectual property. Because every additional month of market exclusivity can mean an extra $50 million or more in revenue, pharma companies have gone to great lengths to block the entry of generic competition.